Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A test for anti-TNF non-responders? Few alternative RA therapies available

This article was originally published in Scrip

Executive Summary

Tumor necrosis factor (TNF) inhibitors, such as Amgen's Enbrel (etanercept) and AbbVie's Humira (adalimumab), are the biologics of choice to treat rheumatoid arthritis (RA) patients. But many people with the debilitating autoimmune disease don't respond to anti-TNF therapies, so what if you could identify patients early on who won't respond to those biologics?

Advertisement

Related Content

ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel